EG
REGN icon

Ellerson Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Ellerson Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.16M Buy
8,282
+203
+3% +$138K 3.05% 10
2026
Q1 		$6.24M Buy
8,079
+44
+0.5% +$33.7K 4.09% 5
2025
Q4 		$6.2M Sell
8,035
-67
-0.8% -$45.5K 4.2% 5
2025
Q3 		$4.56M Buy
8,102
+2,671
+49% +$1.51M 2.83% 10
2025
Q2 		$2.85M Sell
5,431
-2,711
-33% -$1.51M 2.01% 22
2025
Q1 		$5.16M Buy
8,142
+1,222
+18% +$841K 4.11% 4
2024
Q4 		$4.93M Buy
6,920
+59
+0.9% +$49.5K 3.6% 7
2024
Q3 		$7.21M Sell
6,861
-127
-2% -$141K 5.66% 3
2024
Q2 		$7.34M Sell
6,988
-84
-1% -$81.4K 5.59% 4
2024
Q1 		$6.81M Sell
7,072
-23
-0.3% -$21.9K 5.2% 4
2023
Q4 		$6.23M Hold
7,095
– – 5.41% 4
2023
Q3 		$5.84M Sell
7,095
-134
-2% -$105K 5.44% 4
2023
Q2 		$5.19M Buy
7,229
+170
+2% +$131K 4.95% 4
2023
Q1 		$5.8M Sell
7,059
-4
-0.1% -$3.02K 6.29% 4
2022
Q4 		$5.1M Buy
+7,063
New +$5.21M 5.4% 3

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Ellerson Group's REGN Position: Q2 2026 in Review

Ellerson Group increased its Regeneron Pharmaceuticals (REGN) stake by 2.5% in Q2 2026, buying an estimated $138K and bringing the position to 8,282 shares worth $5.16M. The position accounts for 3.05% of the portfolio, ranked #10.

Ellerson Group first reported a position in REGN in Q4 2022 and has held it in 15 quarters since. The position peaked at $7.34M in Q2 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Ellerson Group held 8,282 shares of Regeneron Pharmaceuticals worth $5.16M as of Q2 2026.
  • Ellerson Group bought 203 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $138K.
  • Regeneron Pharmaceuticals made up 3.05% of Ellerson Group's portfolio in Q2 2026, its #10 holding.
  • Ellerson Group first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Ellerson Group's Regeneron Pharmaceuticals position peaked at $7.34M in Q2 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Ellerson Group's 13F filing for Q2 2026, filed 31 Jul 2026.